Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ichthocortin is a topical dermatological combination therapy developed by Ichthyol-Gesellschaft Cordes Hermanni & Co. It is formulated with hydrocortisone acetate, a mild (Class I) corticosteroid, and sodium bituminosulfonate (pale Ichthyol). Hydrocortisone provides anti-inflammatory, anti-allergic, and antipruritic effects by acting as an agonist at the glucocorticoid receptor, thereby suppressing the production of pro-inflammatory cytokines and mediators. Sodium bituminosulfonate, a substance derived from sulfur-rich oil shale, complements this action with its own anti-inflammatory, antimicrobial, and anti-seborrheic properties, which are thought to involve the inhibition of inflammatory mediator release and leukotriene synthesis. Ichthocortin is primarily indicated for the treatment of inflammatory, non-infectious skin conditions such as eczema and various forms of dermatitis where a low-potency corticosteroid is appropriate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocortisone + sodium bituminosulfonate.